Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/09/2005CN1592618A Method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
03/09/2005CN1592617A Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
03/09/2005CN1592616A GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity
03/09/2005CN1592615A Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
03/09/2005CN1592614A Partial dopamine-d 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
03/09/2005CN1592609A Abuse-resistant opioid dosage form
03/09/2005CN1592576A Disruption of the prostaglandin E synthase 2 gene
03/09/2005CN1590408A Preparation technology of globe fish peptide and its medical health care use
03/09/2005CN1590379A New heterocyclic oxime compounds, preparing process and medical composition thereof
03/09/2005CN1590373A Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol
03/09/2005CN1589903A Methods for amyloid removal using anti-amyloid antibodies
03/09/2005CN1589889A Extract of plant dendrobii caulis and preparing process and use thereof
03/09/2005CN1589865A Chinese medicine compound preparation for treating depression and its preparation method
03/09/2005CN1589817A Chinese medicinal extract for dispelling drunk and protecting liver and its preparation method
03/09/2005CN1589797A Lomeilizine hydrochloride oral cavity disintegration tablet and its preparation method
03/09/2005CN1589796A Nicergoline oral cavity disintegration tablet and its preparation method
03/09/2005CN1589795A Nimodiping Freeze dried composition and its preparation method
03/09/2005CN1589788A Modulating multiple lineage kinase proteins
03/09/2005CN1589784A 5-hydroxymethyl -2-furol and its derivative analogue medical use
03/09/2005CN1589778A Microencapsulated saccharomyces and its application
03/09/2005CN1589777A Microencapsulated saccharomyces and its application
03/09/2005CN1589776A Microencapsulated saccharomyces and its application
03/09/2005CN1192112C Mutant herpes simplex viruses and uses thereof
03/09/2005CN1192035C Inhibitors of interleukin-1'beta' converting enzyme
03/09/2005CN1192032C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
03/09/2005CN1192029C Agents for improving learning or memory
03/09/2005CN1192028C Heterocyclic substituted aminoazacycles useful as central nervous system agents
03/09/2005CN1192022C Novel compound
03/09/2005CN1192021C 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands
03/09/2005CN1191860C Method for treatment of fibrosis using antagonist of integrin alpha-4 subunit
03/09/2005CN1191847C Medicated pillow its making process
03/09/2005CN1191826C Pharmaceutical formulation
03/08/2005US6864383 Ophthalmic compositions for treating ocular hypertension
03/08/2005US6864379 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
03/08/2005US6864368 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
03/08/2005US6864355 Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
03/08/2005US6864291 Agonists specific for the peripheral cannabinoid receptor
03/08/2005US6864290 Statine derivatives for the treatment of Alzheimer's disease
03/08/2005US6864277 Brain diosrders; cardiovascular disorders; central nervous system disorders; psychological disorders
03/08/2005US6864271 Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
03/08/2005US6864266 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
03/08/2005US6864263 For therpay of inflammatory bowel disease, cerebral ischemia and arthritis, adult respiratory distress syndrome (ARDS) and myocarditis, as adjuvants to short term immunosuppression in transplant therapy
03/08/2005US6864261 Substituted piperzino-pyridine compound, useful for treting pain, anxiety, urinary incontinence, an addictive disorder, Parkinson's disease, epilepsy, psychosis, and used as Selective antagonists of the metabotropic glutamate receptor 5
03/08/2005US6864257 Usable as tranquillisers and hypnotics
03/08/2005US6864252 Treatment of cyclooxygenase mediated diseases, such as arthritis, neurodegeneration and colon cancer
03/08/2005US6864243 Method for treating retinal degeneration with purinergic receptor agonists
03/08/2005US6863901 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
03/08/2005US6863647 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
03/08/2005US6862890 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/08/2005CA2480712A1 Chondrocyte therapeutic delivery system
03/03/2005WO2005019465A1 Sugar chain-cutting agent
03/03/2005WO2005019219A1 Pyrrolopyrimidinone derivative
03/03/2005WO2005019218A1 Pyrrolopyrimidinethione derivative
03/03/2005WO2005019215A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
03/03/2005WO2005019188A1 Fused pyrimidine derivative and use thereof
03/03/2005WO2005019180A1 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A 5-HT2c RECEPTOR AGONIST
03/03/2005WO2005019157A1 Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition
03/03/2005WO2005018676A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005WO2005018672A1 Drug containing chymase inhibitor as the active ingredient
03/03/2005WO2005018656A1 Agent for preventing and/or ameliorating brain nerve cell death
03/03/2005WO2005018649A1 Agent for inhibiting the formation of final saccharification product
03/03/2005WO2005018648A1 (20S)-1α-HYDROXY-2-METHYLENE-19-NOR-VITAMIN D3 AND ITS USES
03/03/2005WO2005018645A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018632A1 Treatment of neurodegenerative conditions
03/03/2005WO2005018621A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018619A1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
03/03/2005WO2005018614A1 Powder formulation comprising the cgrp antagonist 1- (n2-(3,5-dibromo-n-(4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)- 1-piperidinyl)carbonyl)-d-tyrosyl)-l-lysyl)-4-(4-pyridinyl)-piperazine
03/03/2005WO2005018545A2 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
03/03/2005WO2005018532A2 Purine receptor binding compounds
03/03/2005WO2005018531A2 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
03/03/2005WO2004105766A3 Use of lornoxicam or lornoxicam analogue compounds
03/03/2005WO2004104004A3 Triaza-spiro compounds as nociceptin analogues and uses thereof
03/03/2005WO2004093893A3 Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
03/03/2005WO2004071395A3 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor ox1r (ox1r)
03/03/2005WO2004069182A3 Active immunization to generate antibodies to soluble a-beta
03/03/2005WO2004062554A8 Enhancement of dopaminergic neuron generation and survital
03/03/2005WO2003042362A3 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
03/03/2005WO2003031405A3 Methods for the synthesis of substituted purines
03/03/2005US20050049424 6-Hydroxy isoflavones derivatives and medicaments involving same
03/03/2005US20050049312 N-(1-adamantyl)alkyl]alkano-amidines, guanidines or N'-nitroguanidines; non-competitive receptor antagonists for the NMDA receptor
03/03/2005US20050049308 Apolipoprotein D degradation inhibitor
03/03/2005US20050049303 Adamantane derivatives
03/03/2005US20050049294 Methods of using [3.2.0] heterocyclic compounds and analogs thereof
03/03/2005US20050049293 Increasing effect of released acetylcholine on hepatic muscarinic receptors
03/03/2005US20050049292 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression
03/03/2005US20050049279 Sustained release daily dosage form comprising D-threo methylphenidate; substantially free of L-threo and erythro optical isomers; minimizing side effects, increasing efficacy
03/03/2005US20050049277 Histamine H3 receptor antagonists; such as 2-(4-(n-ethyl)anilinoethoxyphenyl)imidazo[1,2-a]pyridine
03/03/2005US20050049261 Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives
03/03/2005US20050049259 Viricides; for the prophylaxis and treatment of herpes viral infections
03/03/2005US20050049258 Enzyme inhibitors for phosphodiesterase isozymes for treatment of asthma, chronic bronchitis and chronic obstructive pulmonary disease
03/03/2005US20050049251 Inhibitors of p38
03/03/2005US20050049246 Such as [3-(2-Bromo-ethoxy)-phenyl]-[4-(3-cyclohexyl-5-methyl-isoxazol-4-yl)-pyrimidin-2-yl]-amine
03/03/2005US20050049240 Tetrahydroisochinolines, their production and the use thereof as analgesics
03/03/2005US20050049239 Type 2 glycine transporter inhibitors; muscle spasticity, tinnitus, epilepsy neuropathic pain, obesity
03/03/2005US20050049234 Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents
03/03/2005US20050049233 Transdermal administering of testosterone
03/03/2005US20050049205 Product from rose hips e.g. 3- beta -D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO); arthritis and osteoarthritis
03/03/2005US20050049202 For treating disorders associated with excessive cytokine release such as interleukin-1 (IL-1) for example infection, cancer, asthma, coronary restenosis, autoimmune disease, cirrhosis, entotoxemia, reperfusion injury and septic shock; lactone or lactam-benzoates or benzamides
03/03/2005US20050049195 Methods and compositions for nerve regeneration
03/03/2005US20050049190 Cation conducting gabaa receptors and their use
1 ... 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 ... 1833